KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Jazz Pharmaceuticals (JAZZ) EBITDA Margin: 2009-2025

Historic EBITDA Margin for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to 5.11%.

  • Jazz Pharmaceuticals' EBITDA Margin fell 1956.00% to 5.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.86%, marking a year-over-year decrease of 538.00%. This contributed to the annual value of 17.61% for FY2024, which is 252.00% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its EBITDA Margin stood at 5.11% for Q3 2025, which was up 182.04% from -6.23% recorded in Q2 2025.
  • Jazz Pharmaceuticals' EBITDA Margin's 5-year high stood at 26.68% during Q1 2021, with a 5-year trough of -27.09% in Q4 2022.
  • In the last 3 years, Jazz Pharmaceuticals' EBITDA Margin had a median value of 15.29% in 2023 and averaged 12.83%.
  • Within the past 5 years, the most significant YoY rise in Jazz Pharmaceuticals' EBITDA Margin was 6,215bps (2021), while the steepest drop was 4,448bps (2021).
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' EBITDA Margin stood at 5.51% in 2021, then plummeted by 3,260bps to -27.09% in 2022, then skyrocketed by 3,920bps to 12.11% in 2023, then soared by 543bps to 17.53% in 2024, then crashed by 1,956bps to 5.11% in 2025.
  • Its last three reported values are 5.11% in Q3 2025, -6.23% for Q2 2025, and 17.53% during Q4 2024.